Skip to content

Scientific Publications

Page 'Sub' Navigation:

Page Path 'Breadcrumb':

Posters


Efficacy and Safety of RDEA594, a Novel Uricosuric Agent, as Combination Therapy with Allopurinol in Gout Patients: Randomized, Double-Blind, Placebo-Controlled, Phase 2 Experience  Efficacy and Safety of RDEA594, a Novel Uricosuric Agent, as Combination Therapy with Allopurinol in Gout Patients: Randomized, Double-Blind, Placebo-Controlled, Phase 2 Experience




RDEA594, a Novel Uricosuric Agent, Shows Impressive Reductions in Serum Urate Levels as Monotherapy and Substantial Additive Activity in Combination with Febuxostat in Normal Healthy Volunteers  RDEA594, a Novel Uricosuric Agent, Shows Impressive Reductions in Serum Urate Levels as a Monotherapy and Substantial Additive Activity in Combination with Febuxostat in Normal Healthy Volunteers




RDEA594, a Novel Uricosuric Agent, Significantly Reduced Serum Urate Levels and Was Well Tolerated in a Phase 2a Pilot Study in Hyperuricemic Gout Patients


Evaluation of Drug-Drug Interaction Potential Between RDEA594, Allopurinol and Febuxostat in Preclinical Species Evaluation of Drug-Drug Interaction Potential Between RDEA594, Allopurinol and Febuxostat in Preclinical Species

Safety, Pharmacokinetics, and Serum Uric Acid Lowering Effect of RDEA594, A Novel, Uricosuric Agent, In Healthy Volunteers Safety, Pharmacokinetics, and Serum Uric Acid Lowering Effect of RDEA594, A Novel, Uricosuric Agent, In Healthy Volunteers

RDEA594: A Potent URAT1 Inhibitor Without Affecting Other Important Renal Transporters, OAT1 and OAT3 RDEA594: A Potent URAT1 Inhibitor Without Affecting Other Important Renal Transporters, OAT1 and OAT3

Selective MEK1/2 Inhibitors RDEA436 and RDEA119 Exhibit Anti-Inflammatory Efficacy in Mono and Combination Therapy with Methotrexate in Pristane-Induced Arthritis in Rats Selective MEK1/2 Inhibitors RDEA436 and RDEA119 Exhibit Anti-Inflammatory Efficacy in Mono and Combination Therapy with Methotrexate in Pristane-Induced Arthritis in Rats

The Selective MEK Inhibitor RDEA119: Synergy with Multiple Classes of Anti-Cancer Agents The Selective MEK Inhibitor RDEA119: Synergy with Multiple Classes of Anti-Cancer Agents

In Vitro Resistance Selection Study and Favorable PK Properties of RDEA427, a New NNRTI In Vitro Resistance Selection Study and Favorable PK Properties of RDEA427, a New NNRTI

RDEA594, a Potential Uric Acid Lowering Agent through Inhibition of Uric Acid Reuptake, Shows Better Pharmacokinetics than its Prodrug RDEA806 RDEA594, a Potential Uric Acid Lowering Agent through Inhibition of Uric Acid Reuptake, Shows Better Pharmacokinetics than its Prodrug RDEA806

The Effect of MEK Inhibitor RDEA119 on Biomarkers in Advanced Cancer Patients in a Phase 1 Clinical Trial The Effect of MEK Inhibitor RDEA119 on Biomarkers in Advanced Cancer Patients in a Phase 1 Clinical Trial

RDEA594, a Novel Uricosuric Agent, Significantly Reduced Serum Urate Levels and Was Well Tolerated in a Phase 2a Pilot Study in Hyperuricemic Gout Patients RDEA594, a Novel Uricosuric Agent, Significantly Reduced Serum Urate Levels and Was Well Tolera Resistance to RDEA806 Requires Multiple Mutations Which Have Limited Cross-Resistance to Other NNRTI’s

RDEA119: A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer RDEA119: A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer

RDEA119, a Potent and Highly Selective MEK1/2 Inhibitor is Beneficial in Dextran Sulfate Sodium (DSS)-Induced Chronic Colitis in Mice RDEA119, a Potent and Highly Selective MEK1/2 Inhibitor is Beneficial in Dextran Sulfate Sodium (DSS)-Induced Chronic Colitis in Mice

Design and Synthesis of RDEA119 a Potent and Orally Bioavailable MEK Inhibitor Design and Synthesis of RDEA119 a Potent and Orally Bioavailable MEK Inhibitor

Biosynthesis of Oxidative and Conjugated Metabolites of VRX-480773 and Identification of their Structures by LC-MS/MS and NMR Biosynthesis of Oxidative and Conjugated Metabolites of VRX-480773 and Identification of their Structures by LC-MS/MS and NMR

Safety and Uric Acid Lowering Effect in Humans Following Multiple Doses of RDEA806, a Novel Prodrug for the Potential Treatment of Hyperuricemia Safety and Uric Acid Lowering Effect in Humans Following Multiple Doses of RDEA806, a Novel Prodrug for the Potential Treatment of Hyperuricemia

Mode of Action of RDEA594 as a Uric Acid Lowering Agent in Humans Following Multiple Doses of its Pro-drug, RDEA806 Mode of Action of RDEA594 as a Uric Acid Lowering Agent in Humans Following Multiple Doses of its Pro-drug, RDEA806

RDEA119, A Selective MEK 1/2 Inhibitor Ameliorates Experimental Arthritis RDEA119, A Selective MEK RDEA119, A Selective MEK 1/2 Inhibitor Ameliorates Experimental Arthritis

RDEA436, a Novel MEK Inhibitor with Favorable Pharmacokinetic Properties RDEA436, a Novel MEK Inhibitor with Favorable Pharmacokinetic Properties

RDEA119, a Potent and Highly Specific MEK Inhibitor is Efficacious in Mouse Tumor Xenograft Studies RDEA119, a Potent and Highly Specific MEK Inhibitor is Efficacious in Mouse Tumor Xenograft Studies

A Novel NNRTI Class with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses A Novel NNRTI Class with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses

RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses

RDEA 806 IQ Assessment Potent NNRTI An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent Activity Profile in the Presence of Human Serum Proteins An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent Activity Profile in the Presence of Human Serum Proteins

RDEA119: A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer RDEA119: A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer

The Discovery of RDEA806, a Potent New HIV NNRTI in Phase 1 Clinical Trials The Discovery of RDEA806, a Potent New HIV NNRTI in Phase 1 Clinical Trials

RDEA806, a Potent NNRTI with a High Genetic Barrier to Resistance RDEA806, a Potent NNRTI with a High Genetic Barrier to Resistance

Safety and Pharmacokinetics of Ascending Single Oral Doses of RDEA806, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers Safety and Pharmacokinetics of Ascending Single Oral Doses of RDEA806, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers

RDEA806, A Potent Non-Nucleoside Reverse Transcriptase Inhibitor with Less Potential for Drug-Drug Interactions RDEA806, A Potent Non-Nucleoside Reverse Transcriptase Inhibitor with Less Potential for Drug-Drug Interactions